TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01319487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2304 Eye Drops High Dose
Description: 2304 Eye Drops High Dose self-administered in the study eye during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2304 Eye Drops Low Dose
Description: 2304 Eye Drops Low Dose self-administered in the study eye during the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Eye Drops
Description: Placebo Eye Drops self-administered in the study eye during the treatment period
Study: NCT01928199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04663932

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: immediate stenting group(one-step strategy)
Description: Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deferred stenting group (two-step strategy)
Description: Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
Study: NCT06435078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mPETS(modified-PETS system)
Description: The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mPETS(modified-PETS system)
Description: The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
Study: NCT01616758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024 9mg
Study: NCT02107313

Intervention type: DRUG
Group type: OTHER
Intervention: Fed Cohort PBT2
Description: PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.

Intervention type: DRUG
Group type: OTHER
Intervention: Fasted Cohort PBT2
Description: PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
Study: NCT00190398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting with cerebral protection
Description: Carotid angioplasty and stenting with cerebral protection
Study: NCT01247389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic colectomy
Description: Laparoscopic segmental colectomy with planned abdominal extraction site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic colectomy
Description: Laparoscopic segmental colectomy with planned abdominal extraction site
Study: NCT02315664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education session, Fitbit Flex, and remote coaching by a PT
Description: Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Same intervention with a 2 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
Study: NCT03479138

Intervention type: DIAGNOSTIC_TEST
Intervention: Induced sputum
Description: Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome

Intervention type: DIAGNOSTIC_TEST
Intervention: Induced sputum
Description: Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
Study: NCT05208268

Intervention type: DRUG
Intervention: Pariet
Description: Pariet Tablets.
Study: NCT01628692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Capsule, oral, 150 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Capsule, oral, 150 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Capsule, oral, 150 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Capsule, oral, 150 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 500-600 mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 500-600 mg, twice daily
Study: NCT03913169

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Implementation of Interprofessional Curriculum
Description: The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Implementation of Interprofessional Curriculum
Description: The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Implementation of Interprofessional Curriculum
Description: The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Implementation of Interprofessional Curriculum
Description: The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
Study: NCT01341249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental DW224aa
Description: DW224aa tablet, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental DW224a
Description: DW224a capsule, single dose
Study: NCT02757313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose THC marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose THC marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose THC marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose THC marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo marijuana
Study: NCT02394652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an antidiabetic agent given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an antineoplastic agent given intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is an antineoplastic agent given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAZA
Description: FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAZA
Description: FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
Study: NCT01684618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS Oximetry + CPAP
Description: CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
Study: NCT03632083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hy-Care Contact Lens Solution
Description: Hy-Care Contact Lens Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lite Contact Lens Solution
Description: Lite Contact Lens Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A soft contact lens
Description: fanfilcon A soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A soft contact lens
Description: fanfilcon A soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A soft contact lens
Description: comfilcon A soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A soft contact lens
Description: comfilcon A soft contact lens
Study: NCT02247843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: βAS3-FB vector transduced peripheral blood CD34+ cells
Description: CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
Study: NCT01087515

Intervention type: OTHER
Group type: OTHER
Intervention: Blood donation
Description: In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects.
Study: NCT05809336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine 0.2g orally 3 times/day
Description: inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1/PD-L1 inhibitor ,chemotherapy/targeting
Description: PD-1/PD-L1 inhibitor ± chemotherapy/targeting
Study: NCT00927498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional chemotherapy (AraC + Daunorubicin),
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.
Study: NCT04245345

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer Sensing for Micra AV Study
Description: Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
Study: NCT02472054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Prednisolone (MP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Study: NCT01729468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin, 160 mg per day until 34 weeks of gestation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 160 mg per day until 34 weeks of gestation
Study: NCT02872012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia device
Description: The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia device
Description: The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia device
Description: The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia device
Description: The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia device
Description: The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine applied to the non-cryoanesthesia eye.
Study: NCT00741832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conical Positive Expiratory Pressure Device (C-PEP)
Description: Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control breathing
Description: Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
Study: NCT01834586

Intervention type: DRUG
Group type: OTHER
Intervention: Anesthetic Topical Adhesive Synera
Description: For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week
Study: NCT00265720

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Written materials only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced out of pocket expense
Description: Reimbursed up to $500 out of pocket expense for CRC screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one on one education
Description: one on one education with a health educator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group education
Description: Education in a small group
Study: NCT01380977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Crime group intervention
Description: A group intervention for 16 1.5 hr sessions held twice a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Crime group intervention
Description: A group intervention for 16 1.5 hr sessions held twice a week
Study: NCT00440245

Intervention type: DRUG
Group type: OTHER
Intervention: salbutamol
Description: 200 micrograms salbutamol from MDI
Study: NCT03446638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved drug or combination of drugs
Description: Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAG induction
Description: Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count \> 500/ microliter for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7 + 3 induction
Description: Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine
Description: Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care alone
Description: Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
Study: NCT00497341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
Study: NCT01962194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer.
Study: NCT01031004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon B
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study: NCT05393687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: progressive eccentric exercise with elastic band
Study: NCT03996122

Intervention type: OTHER
Intervention: fMRI
Description: 3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
Study: NCT03446638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational biology simulations software
Description: Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
Study: NCT00285376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: titration to 40mg tablets qd for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vilazodone
Description: titration to 40mg tablets qd for 8 weeks
Study: NCT04353206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
Description: Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
Study: NCT02833961

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study: NCT03980197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active surveillance and preemptive isolation
Description: Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
Study: NCT02722811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 8 weeks
Study: NCT02625246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSCs
Description: intravenous infusion of bone marrow-derived allogeneic stem cells
Study: NCT01580683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo
Description: Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
Study: NCT00460668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: 2 or 3 times a week during 8 weeks